New Study Showcases Efficacy of
SonoRepro™
NEW
YORK and TOKYO,
Dec. 14,
2023 /PRNewswire/ - Pixie Dust Technologies,
Inc. (Nasdaq: PXDT) (the
"Company"), a Japanese technology company
focused on commercializing innovative products and materials
utilizing proprietary wave control technology, today announced that
a Company-sponsored experiment on the Company's SonoRepro™ product
was recently conducted by Dr. Akinobu
Miyata, Director of Miyata Medical Clinic, in collaboration
with the Japan Clinical Trial Association (JACTA).
The study, aimed at determining the effects on the scalp and
hair when using SonoRepro™ with scalp lotion for 12 weeks,
consisted of adult men and women under 49 years old who were
concerned about thinning hair. The goal of the study was to utilize
a test group and control group to determine whether results were
significant.
As part of the study, scalp lotion was applied to the top of the
head, and ultrasonic waves were irradiated to the scalp by
SonoRepro™ to cover the center of the application area.
SonoRepro™'s non-contact vibrotactile stimulation is a technology
that irritates the skin without physically touching it, using
ultrasonic waves transmitted through the air.
In comparing the results of the test group with the control
group, the outcome revealed that the study participants who
received treatment via SonoRepro™ showed a meaningful improvement
in hair diameter, head condition, and scalp water content.
"The recent study evidenced the efficacy of our technology
across both genders and different age groups," said Pixie Dust
Technologies, Inc. CRO Takayuki
Hoshi. "Moving forward, we intend to further explore the
potential of our wave control technology in the healthcare
sector."
Forward-Looking
Statements
Certain statements contained in this press release are
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements reflect the Company's current
expectations or beliefs concerning future events and actual events
may differ materially from current expectations. Any such
forward-looking statements are subject to various risks and
uncertainties, including the strength of the economy, changes to
the market for securities, political or financial instability and
other factors which are set forth in the Company's Annual Report on
Form 20-F for the year ended April 30,
2023 (File No. 001-41749) filed with the SEC, and in all
filings with the SEC made by the Company subsequent to the filing
thereof. The Company does not undertake to publicly update or
revise its forward-looking statements, whether as a result of new
information, future events or otherwise.
About Pixie Dust Technologies,
Inc.
Pixie Dust Technologies, Inc. is a Japanese technology company
focused on commercializing innovative products and materials
utilizing proprietary wave technology. The Company is currently
focusing on two areas of product development: (1) "Personal Care
& Diversity", where wave control technology is applied to
mechanobiology and intervention/assistance in vision, hearing, and
touch, and (2) "Workspace & Digital Transformation," where
metamaterials (technology that creates properties through structure
rather than material) and solutions to commercial design problems,
such as in offices or construction sites, are applied.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sonorepro-by-pixie-dust-technologies-inc-featured-in-medical-practice-and-new-drugs-2023-study-302015303.html
SOURCE Pixie Dust Technologies